ITOS News and Press, iTeos Therapeutics Inc. From 12/15/23

2023-12-15 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management...

iTeos Therapeutics Inc. (ITOS) is expected to report $-1.2 for Q3 2023

2023-11-07 08:26:49 ET More on iTeos Therapeutics iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall Seeking Alpha’s Quant Rating on iTeos Therapeutics Historical earnings da...

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma - Completed enrollment ...

2023-11-04 09:00:00 ET Summary iTeos Therapeutics is a clinical-stage biotech focused on developing immunotherapies for solid tumors, with a focus on non-small cell lung cancer (NSCLC). Their most advanced project is belrestotug, an antibody targeting the TIGIT immune checkpoint, ...

2023-10-11 18:04:12 ET S&P Dow Jones Indices said Wednesday that NCR Atleos ( NATL ) will replace iTeos Therapeutics ( ITOS ) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. iTeos Therapeutics is no longer representative of t...

NCR Atleos Set to Join S&P SmallCap 600 NCR Atleos Set to Join S&P SmallCap 600 PR Newswire NEW YORK , Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective ...

WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company m...

2023-08-23 13:11:49 ET Gainers: VCI Global Limited ( VCIG ) +107% . Mercurity Fintech Holding ( MFH ) +44% . Apellis Pharmaceuticals ( APLS ) +32% . iTeos Therapeutics ( ITOS ) +27% . Hitek Global ( HKIT ) +26% . Aditxt ( A...